2170 Stock Overview
An investment holding company provides genetic testing solutions for assisted human reproduction in the People’s Republic of China and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Suzhou Basecare Medical Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.71 |
| 52 Week High | HK$3.30 |
| 52 Week Low | HK$1.71 |
| Beta | 0.51 |
| 11 Month Change | -9.52% |
| 3 Month Change | -25.97% |
| 1 Year Change | -46.23% |
| 33 Year Change | -90.21% |
| 5 Year Change | n/a |
| Change since IPO | -93.83% |
Recent News & Updates
Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet
May 30
Suzhou Basecare Medical Corporation Limited's (HKG:2170) Shares Leap 27% Yet They're Still Not Telling The Full Story
May 09Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch
Mar 22Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet
May 30Suzhou Basecare Medical Corporation Limited's (HKG:2170) Shares Leap 27% Yet They're Still Not Telling The Full Story
May 09Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch
Mar 22Is There An Opportunity With Suzhou Basecare Medical Corporation Limited's (HKG:2170) 47% Undervaluation?
Aug 01Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) 27% Price Drop
May 26Are Investors Undervaluing Suzhou Basecare Medical Corporation Limited (HKG:2170) By 48%?
Jul 20Shareholder Returns
| 2170 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -5.0% | 1.4% | -0.7% |
| 1Y | -46.2% | -49.0% | -4.0% |
Return vs Industry: 2170 exceeded the Hong Kong Medical Equipment industry which returned -49% over the past year.
Return vs Market: 2170 underperformed the Hong Kong Market which returned -4% over the past year.
Price Volatility
| 2170 volatility | |
|---|---|
| 2170 Average Weekly Movement | 8.0% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.1% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2170's share price has been volatile over the past 3 months.
Volatility Over Time: 2170's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 586 | Bo Liang | www.basecare.cn |
Suzhou Basecare Medical Corporation Limited, an investment holding company provides genetic testing solutions for assisted human reproduction in the People’s Republic of China and Australia. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also offers liquid nitrogen storage dewar, Cryopreservation system, and sperm quality analyzer; universal kits for sequencing effects; sample preservation solution; and nucleic acid purification and DNA extraction kits.
Suzhou Basecare Medical Corporation Limited Fundamentals Summary
| 2170 fundamental statistics | |
|---|---|
| Market cap | HK$467.73m |
| Earnings (TTM) | -HK$207.13m |
| Revenue (TTM) | HK$224.73m |
2.1x
P/S Ratio-2.3x
P/E RatioIs 2170 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2170 income statement (TTM) | |
|---|---|
| Revenue | CN¥207.98m |
| Cost of Revenue | CN¥116.63m |
| Gross Profit | CN¥91.35m |
| Other Expenses | CN¥283.04m |
| Earnings | -CN¥191.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | 43.92% |
| Net Profit Margin | -92.17% |
| Debt/Equity Ratio | 19.3% |
How did 2170 perform over the long term?
See historical performance and comparison